Dr. Linda D'Amore
Operational Manager, GeneMill Foundry
Dr. Linda D’Amore is Operational Manager at the GeneMill Foundry in Liverpool. One of four foundries funded by the BBSRC, it is also part of the Centre for Genomic Research, which offers high-throughput genomics platform analysis. Specifically, GeneMill provides high-throughput construction and testing of synthetic DNA constructs, using a variety of platforms.
Dr. Linda D’Amore is Operational Manager at the GeneMill Foundry in Liverpool. One of four foundries funded by the BBSRC, it is also part of the Centre for Genomic Research, which offers high-throughput genomics platform analysis.
Dr. D’Amore discusses how miniaturization of synthetic biology has reduced working volumes from 1.5 ml to < 0.5 ml and from 96-well plates to microliter reactions in 1536-well plates. The challenge now is to reduce and automate routine liquid handling to the nanoliter scale.
GeneMill provides high-throughput construction and testing of synthetic DNA constructs, using a variety of platforms including next-generation sequencing using Illumina and PacBio, and expression analysis using arrays and nanostring.
Dr. D’Amore describes the standard synbio workflow used by GeneMill: DNA constructs are designed in silico. Functional parts are synthesized or retrieved and then combined at the nanoliter scale using Labcyte’s Echo liquid handler. Constructs are assembled and sequence validated using PacBio. Constructs are then assayed for function and used for biochemical assays or metabolite analysis (Johnson et al., 2016).
Opportunities and challenges presented by miniaturization are examined in more detail. There are numerous benefits to reducing sample size, reagent volume and analysis time. Reproducibility becomes more of an issue with miniaturization, as does the need for additional optimization and quality control (QC). Ultimately, miniaturization reduces costs and enables more ambitious experimental design, allowing more variables and replicates to be tested, which pushes the boundaries of what facilities like GeneMill can achieve.
Dr D’Amore presents data from an intensive Cold Spring Harbor Laboratories course she attended on synthetic biology, where she was able to apply miniaturization principles to experimental design for TX-TL and CRISPR technologies. Dr D'Amore generated a series of constructs for testing under different conditions to examine the effect of guide RNAs, ssDNA and dsDNAs for targeting GFP expression. Finally, Dr D’Amore describes a new miniaturized system for plasmid QC, using the wide variety of platforms GeneMill have at their disposal for larger construct assembly and verification. Classical synthetic plasmid construction methods work well for small inserts but can fail for larger inserts over 10 kb. By combining Labcyte’s acoustic liquid handlers with the PacBio system it is possible to create a one pot miniaturization system.
The idea was to take all the constructs together, assuming they are different enough for multiplexing and then use the adaptor barcodes for screening colonies and pooling the plasmids together. Basically you have a single reaction where the constructs, the Type II enzyme, the smart bell and the ligase are all in one pot.”
The platform is still in its early stages but initial results are encouraging and about to be published. Dr D’Amore is now working towards multiplexing the reactions using the Echo liquid handler.